Back to Journals » Vascular Health and Risk Management » Volume 8

Critical evaluation of the efficacy and tolerability of azilsartan

Authors De Caterina A, Harper A, Cuculi

Received 9 March 2012

Accepted for publication 10 April 2012

Published 14 May 2012 Volume 2012:8 Pages 299—305


Review by Single anonymous peer review

Peer reviewer comments 4

Alberto R De Caterina1,2, Andrew R Harper2,3, Florim Cuculi2

1Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy; 2Oxford University Hospitals, Oxford; 3Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom

Abstract: Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.

Keywords: azilsartan medoxomil, angiotensin receptor blocker, hypertension

Corrigendum for this paper has been pubilshed.

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.